Hirudin versus heparin for use in whole blood in vitro biocompatibility models
- 9 May 2008
- journal article
- research article
- Published by Wiley in Journal of Biomedical Materials Research Part A
- Vol. 89A (4), 951-959
- https://doi.org/10.1002/jbm.a.32034
Abstract
Heparin has traditionally been a widely used anticoagulant in blood research, but has been shown to be inappropriate for work with the complement system because of its complement‐interacting properties. In this work, we have compared the effects of heparin with those of the specific thrombin inhibitor hirudin on complement and blood cells in vitro. Whole blood collected in the presence of hirudin (50 μg/mL) or heparin (1 IU/mL) was incubated in the slide chamber model. The plasma was analyzed for complement activation markers C3a and sC5b‐9, and the polyvinylchloride test slides were stained for adhering cells. The integrity of the complement system was tested by incubating serum and hirudin‐treated plasma in the presence of various activating agents. In contrast to heparin, the addition of hirudin generally preserved the complement reactivity, and complement activation in hirudin plasma closely resembled that in normal serum. Importantly, immunochemical staining of surface‐bound cells demonstrated the inducible expression of tissue factor on bound monocytes from hirudin‐treated blood, an effect that was completely abolished in heparin‐treated blood. Our results indicate that hirudin as an anticoagulant produces more physiological conditions than heparin, making hirudin well‐suited for in vitro studies, especially those addressing the regulation of cellular processes. © 2008 Wiley Periodicals, Inc. J Biomed Mater Res, 2009Keywords
This publication has 38 references indexed in Scilit:
- Nanoporesize affects complement activationJournal of Biomedical Materials Research Part A, 2008
- Complement and coagulation: strangers or partners in crime?Trends in Immunology, 2007
- Complement activation and cytokine response by BioProtein, a bacterial single cell proteinClinical and Experimental Immunology, 2007
- Platelets and tissue factorPlatelets, 2005
- Endothelial cell protection and complement inhibition in xenotransplantation: a novel in vitro model using whole bloodXenotransplantation, 2005
- Optimal heparin surface concentration and antithrombin binding capacity as evaluated with human non‐anticoagulated blood in vitroJournal of Biomedical Materials Research Part A, 2003
- Biphasic response of complement to heparin: Fluid-phase generation of neoantigens in human serum and in a reconstituted alternative pathway amplification cycleAmerican Journal of Hematology, 1995
- Modification of the Complement Binding Properties of Polystyrene: Effects of End‐Point Heparin AttachmentScandinavian Journal of Immunology, 1993
- The functional domain of hirudin, a thrombin‐specific inhibitorFEBS Letters, 1983
- Molecular characterization of the complement activating protein in the venom of the Indian cobra (Naja n. siamensis)Molecular Immunology, 1981